Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, a tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

The Liver Failure pipeline drugs market research report provides comprehensive information on the therapeutics under development for Liver Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Liver Failure and features dormant and discontinued projects.

Liver Failure Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Liver Failure pipeline drugs market are Caspase, Dual Specificity Mitogen Activated Protein Kinase Kinase 4, Toll Like Receptor 4, Tumor Necrosis Factor, and Androgen Receptor  among others. Caspase leads this segment of the Liver Failure pipeline drugs market.

Liver Failure Pipeline Drugs Market Analysis, by Targets

Liver Failure Pipeline Drugs Market Analysis, by TargetsFor more Liver Failure pipeline drugs market target insights, download a free report sample

Liver Failure Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Liver Failure pipeline drugs market are Caspase Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 4 Inhibitor, Toll Like Receptor 4 Antagonist, and Tumor Necrosis Factor Inhibitor among others . Caspase Inhibitor leads the Liver Failure pipeline drugs market in terms of MoA.

Liver Failure Pipeline Drugs Market Analysis, by Mechanisms of Action

Liver Failure Pipeline Drugs Market Analysis, by Mechanisms of Action

 For more mechanisms of action insights into the Liver Failure pipeline drugs market, download a free report sample

Liver Failure Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Liver Failure pipeline drugs market are intravenous, oral, intraperitoneal, intramuscular, and parenteral among others. Intravenous leads the Liver Failure pipeline drugs market in terms of RoA.

Liver Failure Pipeline Drugs Market Analysis, by Routes of Administration

Liver Failure Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Liver Failure pipeline drugs market, download a free report sample

Liver Failure Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Liver Failure pipeline drugs market are small molecule, cell therapy, biologic, oligonucleotide, and blood derivative among others. Small Molecule leads the Liver Failure pipeline drugs market in terms of molecule types.

Liver Failure Pipeline Drugs Market Analysis, by Molecule Types

Liver Failure Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule-type insights into the Liver Failure pipeline drugs market, download a free report sample

Liver Failure Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Liver Failure pipeline drugs market are Akaza Bioscience Ltd, Cellaion SA, Genfit SA, HepaRegeniX GmbH, Immune Pharmaceuticals Inc, and Jiangsu Hengrui Medicine Co Ltd among others. CellionBioMed Inc has the highest number of products under development.

Liver Failure Pipeline Drugs Market Analysis, by Companies

Liver Failure Pipeline Drugs Market Analysis, by CompaniesTo know more about the Liver Failure pipeline drugs market companies, download a free report sample

Liver Failure Pipeline Drugs Market Report Overview

Key Targets Caspase, Dual Specificity Mitogen Activated Protein Kinase Kinase 4, Toll Like Receptor 4, Tumor Necrosis Factor, and Androgen Receptor among others
Key Mechanisms of Action Caspase Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 4 Inhibitor, Toll Like Receptor 4 Antagonist, and Tumor Necrosis Factor Inhibitor among others
Key Routes of Administration Intravenous, Oral, Intraperitoneal, Intramuscular, and Parenteral among others
Key Molecule Types Small Molecule, Cell Therapy, Biologic, Oligonucleotide, and Blood Derivative among others
Key Companies Akaza Bioscience Ltd, Cellaion SA, Genfit SA, HepaRegeniX GmbH, Immune Pharmaceuticals Inc, and Jiangsu Hengrui Medicine Co Ltd among others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure.
  • The pipeline guide reviews pipeline therapeutics for Liver Failure by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Failure therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Failure therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Liver Failure

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Failure.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Liver Failure pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Akaza Bioscience Ltd
Arch Biopartners Inc
Bopin (Shanghai) Biomedical Technology Co Ltd
Bristol-Myers Squibb Co
Cellaion SA
Creative Medical Technology Holdings Inc
EA Pharma Co Ltd
Egetis Therapeutics AB
Evive Biotech
Galmed Pharmaceuticals Ltd
Genesen Co Ltd
Genfit SA
GoLiver Therapeutics
Grifols SA
HepaRegeniX GmbH
Immune Pharmaceuticals Inc
iTolerance Inc
Jiangsu Hengrui Medicine Co Ltd
Mina Therapeutics Ltd
Mitopower LLC
Orgenesis Inc
Pittsburgh ReLiver Inc
PrimeGen Global Inc
Proterris Inc
Rejuvenation Technologies Inc
SeaBeLife Spas
Shiftbio Co Ltd
SK Life Science Inc
The Healthy Aging Co
Tianjin Angsai Cell Genetic Engineering Co Ltd
Unicyte AG
Versantis AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Failure (Hepatic Insufficiency) – Overview

Liver Failure (Hepatic Insufficiency) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Failure (Hepatic Insufficiency) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Failure (Hepatic Insufficiency) – Companies Involved in Therapeutics Development

Liver Failure (Hepatic Insufficiency) – Drug Profiles

Liver Failure (Hepatic Insufficiency) – Dormant Projects

Liver Failure (Hepatic Insufficiency) – Discontinued Products

Liver Failure (Hepatic Insufficiency) – Product Development Milestones

Featured News & Press Releases

Jun 24, 2022: Versantis presents new VS-01 data at The International Liver Congress 2022

Nov 15, 2021: Versantis to present positive phase 1b data at AASLD for VS-01 in patients with decompensated Cirrhosis

Nov 09, 2021: GENFIT announces first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program

Feb 01, 2021: Creative Medical Technology Holdings identifies and files patent on novel mechanism of ImmCelz therapeutic activity

Jun 29, 2020: GoLiver Therapeutics receives a positive scientific advice from the European Medicines Agency (EMA) on its clinical development and biomanufacturing strategy for acute liver failure

Jan 08, 2020: Promethera announces initiation of phase 2b DHELIVER study of HepaStem in patients with acute-on-chronic liver failure (ACLF)

Dec 31, 2019: Versantis’ main patent allowed in the USA.

Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world’s first stem cell therapy trial using HepaStem in acute-on-chronic liver failure

May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world’s first liver stem cell therapy in late-stage NASH patients

Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world’s first stem cell clinical trial in ACLF at The International Liver Congress/ EASL 2019

Mar 31, 2019: Versantis: Main patent for VS-01 granted in two additional countries.

Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF

Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April

Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada

Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Liver Failure (Hepatic Insufficiency) – Dormant Projects, 2022

Liver Failure (Hepatic Insufficiency) – Dormant Projects, 2022 (Contd..1)

Liver Failure (Hepatic Insufficiency) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.